The development of a neonatal rotavirus vaccine has taken a step forward through the joint efforts of Australian and New Zealand researchers, with the publication of a phase 2a clinical trial demonstrating safety and immunogenicity of the RV3-BB human neonatal rotavirus vaccine. The study was published online on the 27th August in the journal Lancet […]

Read more

The PRV program was initially adopted by the FDA in 2007 to incentivise the development of drugs to treat neglected tropical diseases (NTDs) (see list below), which would ordinarily attract little, if any, pharmaceutical development interest. Under the scheme, companies with any newly approved drug intended to treat a designated NTD become eligible to receive […]

Read more

Source: Medicines Development Based on a review of quality, safety and efficacy, the TGA approved the registration of ivermectin for the treatment of scabies. Ivermectin is an easy, effective oral treatment for scabies, and is now registered for this purpose in Australia.

Read more

LONDON – UK: The Global Health Investment Fund (GHIF) and Medicines Development for Global Health (Medicines Development) announced today a 10 million USD program for the registration of moxidectin for the treatment of river blindness (onchocerciasis). River blindness is a debilitating neglected tropical disease caused by the worm Onchocerca volvulus, which is transmitted through the […]

Read more

The Global Health Investment Fund (GHIF) has committed US$ 10 million to support completing the dossier for the registration of moxidectin for the treatment of onchocerciasis. Medicines Development for Global Health (MDGH), an Australian not-for-profit biopharmaceutical company, will be managing the work. WHO/TDR/Andy Craggs Onchocerciasis, also known as river blindness, is a debilitating parasitic infection. […]

Read more

Source: Medicines Development Medicines Development is working on the registration of a new game changing treatment for river blindness and scabies. According to the current legislation, with the registration of the new treatment MDL will be eligible for a Priority Review Voucher from the FDA. Click here for details on the FDA voucher scheme.

Read more

Source: Medicines Development Since August 2011 Medicines Development has been supporting the RV3 Rotavirus Vaccine team at the Murdoch Childrens Research Institute (MCRI) by helping to coordinate the development of MCRI’s novel vaccine to protect newborns from rotavirus infection. The new rotavirus vaccine candidate has reached a pivotal milestone after clinical trials results found the […]

Read more

Source: Medicines Development The Department of Microbiology at Monash University and Medicines Development Limited, one of Australia’s specialist providers of development management services for the biotech and pharmaceutical industries, are joining forces to assess a new treatment for Clostridium difficile disease. Infection with the bacterium Clostridium difficile is one of the world’s most significant gut […]

Read more

Source: Medicines Development Medicines Development and Hatchtech are pleased to announce that Michael Wheatcroft has joined Hatchtech as Senior Development Manager under the Development Manager training and placement initiative supported by the Victorian Government’s Smart SME’s Innovation and Commercialisation Program. While remaining an employee of Medicines Development, Michael will be a part of the Hatchtech […]

Read more

Source: Medicines Development Researchers at the Peter MacCallum Cancer Centre, The Auckland Cancer Society Research Centre, Monash University School of Biomedical Sciences and the Queensland Institute of Medical Research aim to develop a new class of immune-suppressive drugs that protect transplanted bone marrow stem cells against immune destruction. Medicines Development is pleased to be providing […]

Read more